Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design

Jozef Bartunek, Beth Davison, Warren Sherman, Thomas Povsic, Timothy D Henry, Bernard Gersh, Marco Metra, Gerasimos Filippatos, Roger Hajjar, Atta Behfar, Christian Homsy, Gad Cotter, William Wijns, Michal Tendera, Andre Terzic, Jozef Bartunek, Beth Davison, Warren Sherman, Thomas Povsic, Timothy D Henry, Bernard Gersh, Marco Metra, Gerasimos Filippatos, Roger Hajjar, Atta Behfar, Christian Homsy, Gad Cotter, William Wijns, Michal Tendera, Andre Terzic

Abstract

Aims: Cardiopoiesis is a conditioning programme that aims to upgrade the cardioregenerative aptitude of patient-derived stem cells through lineage specification. Cardiopoietic stem cells tested initially for feasibility and safety exhibited signs of clinical benefit in patients with ischaemic heart failure (HF) warranting definitive evaluation. Accordingly, CHART-1 is designed as a large randomized, sham-controlled multicentre study aimed to validate cardiopoietic stem cell therapy.

Methods: Patients (n = 240) with chronic HF secondary to ischaemic heart disease, reduced LVEF (<35%), and at high risk for recurrent HF-related events, despite optimal medical therapy, will be randomized 1:1 to receive 600 × 10(6) bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter or a sham procedure. The primary efficacy endpoint is a hierarchical composite of mortality, worsening HF, Minnesota Living with Heart Failure Questionnaire score, 6 min walk test, LV end-systolic volume, and LVEF at 9 months. The secondary efficacy endpoint is the time to cardiovascular death or worsening HF at 12 months. Safety endpoints include mortality, readmissions, aborted sudden deaths, and serious adverse events at 12 and 24 months.

Conclusion: The CHART-1 clinical trial is powered to examine the therapeutic impact of lineage-directed stem cells as a strategy to achieve cardiac regeneration in HF populations. On completion, CHART-1 will offer a definitive evaluation of the efficacy and safety of cardiopoietic stem cells in the treatment of chronic ischaemic HF.

Trial registration: NCT01768702.

Keywords: Cardiopoiesis; Heart failure; Ischaemic cardiomyopathy; Regenerative medicine; Stem cell.

© 2015 The Authors European Journal of Heart Failure © 2015 European Society of Cardiology.

Figures

Figure 1
Figure 1
Study flow chart. MSC, mesenchymal stem cells.
Figure 2
Figure 2
Cardiopoietic stem cell procurement and processing prior to the delivery procedure. Following bone marrow harvest, mesenchymal stem cells (MSCs) are purified and expanded. Following standard operating procedures, cardiopoiesis is imposed for lineage guidance of MSCs to derive cardiopoietic stem cells. Stem cells meeting pre‐defined release criteria are delivered in an autologous fashion to patients with ischaemic cardiomyopathy using a catheter‐based endomyocardial delivery procedure.
Figure 3
Figure 3
Catheter‐based delivery system. Endomyocardial delivery catheter designed for enhanced endomyocardial retention of stem cells (C‐Cathez®) features a thumbwheel control for distal catheter tip deflection (upper left panel), a curved needle design with side holes (inset), and a luer lock connector for study injection with adjustable needle advancing mechanism (lower left).

References

    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després J, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB. Heart Disease and Stroke Statistics—2015 update: a report from the American Heart Association. Circulation 2015;131:e29–e322.
    1. Braunwald E. The war against heart failure; the Lancet lecture. Lancet 2014;385:812–824.
    1. Bartunek J, Vanderheyden M, Hill J, Terzic A. Cells as biologics for cardiac repair in ischaemic heart failure. Heart 2010;96:792–800.
    1. Lin Z, Pu WT. Strategies for cardiac regeneration and repair. Sci Transl Med 2014;6:239rv1.
    1. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013;113:810–834.
    1. Telukuntla KS, Suncion VY, Schulman IH, Hare JM. The advancing field of cell‐based therapy: insights and lessons from clinical trials. J Am Heart Assoc 2013;2:e000338.
    1. Menasché P. Stem cells in the management of advanced heart failure. Curr Opin Cardiol 2015;30:179–185.
    1. Terzic A, Behfar A. Regenerative heart failure therapy headed for optimization. Eur Heart J. 2014;35:1231–1234.
    1. Jeevanantham V, Butler M, Saad A, Abdel‐Latif A, Zuba‐Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long‐term improvement in cardiac parameters: a systematic review and meta‐analysis. Circulation. 2012;126:551–568.
    1. Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin‐Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev 2014;4:CD007888.
    1. Behfar A, Crespo‐Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair: lessons from clinical trials. Nat Rev Cardiol 2014;11:232–246.
    1. Cogle CR, Wise E, Meacham AM, Zierold C, Traverse JH, Henry TD, Perin EC, Willerson JT, Ellis SG, Carlson M, Zhao DX, Bolli R, Cooke JP, Anwaruddin S, Bhatnagar A, da Graca Cabreira‐Hansen M, Grant MB, Lai D, Moyé L, Ebert RF, Olson RE, Sayre SL, Schulman IH, Bosse RC, Scott EW, Simari RD, Pepine CJ, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN) . Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res 2014;115:867–874.
    1. Behfar A, Terzic A. Stem cells versus senescence: the yin and yang of cardiac health. J Am Coll Cardiol 2015;65:148–150.
    1. Behfar A, Terzic A. Stem cell in the rough: repair quotient mined out of a bone marrow niche. Circ Res 2014;115:814–816.
    1. Behfar A, Yamada S, Crespo‐Diaz R, Nesbitt JJ, Rowe LA, Perez‐Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010;56:721–734.
    1. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo‐Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Cardiopoietic stem cell therapy in heart failure: the C‐CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage‐specified biologics. J Am Coll Cardiol 2013;61:2329–2338.
    1. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001;7:176–182.
    1. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med 1999;18:1341–1354.
    1. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living With Heart Failure Questionnaire: reliability and validity during a randomized, double‐blind, placebo‐controlled trial of pimobendan. Pimobendan multicenter research group. Am Heart J 1992;124:1017–1025.
    1. Behfar A, Latere JP, Bartunek J, Homsy C, Daro D, Crespo‐Diaz RJ, Stalboerger PG, Steenwinckel V, Seron A, Redfield MM, Terzic A. Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ Cardiovasc Interv 2013;6:710–718.
    1. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539–5422.
    1. Povsic TJ, O'Connor CM, Henry T, Taussig A, Kereiakes DJ, Fortuin FD, Niederman A, Schatz R, Spencer Rt, Owens D, Banks M, Joseph D, Roberts R, Alexander JH, Sherman W. A double‐blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J 2011;162:654–662.
    1. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W, Botker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyongyosi M, Sylven C. Direct intramyocardial plasmid vascular endothelial growth factor‐a165 gene therapy in patients with stable severe angina pectoris: a randomized double‐blind placebo‐controlled study—The Euroinject One trial. J Am Coll Cardiol 2005;45:982–988.
    1. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha‐Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393–1401.
    1. Zannad F, Stough WG, Piña IL, Mehran R, Abraham WT, Anker SD, De Ferrari GM, Farb A, Geller NL, Kieval RS, Linde C, Redberg RF, Stein K, Vincent A, Woehrle H, Pocock SJ. Current challenges for clinical trials of cardiovascular medical devices. Int J Cardiol 2014;175:30–37.
    1. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Pina IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013;15:1082–1094.
    1. Alla F, Briancon S, Guillemin F, Juilliere Y, Mertes PM, Villemot JP, Zannad F. Self‐rating of quality of life provides additional prognostic information in heart failure. Insights into the Epical study. Eur J Heart Fail 2002;4:337–343.
    1. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac‐resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.
    1. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Res 2000;2:271–278.
    1. Lefevre T, Kappetein AP, Wolner E, Nataf P, Thomas M, Schachinger V, De Bruyne B, Eltchaninoff H, Thielmann M, Himbert D, Romano M, Serruys P, Wimmer‐Greinecker G. One year follow‐up of the multi‐centre European Partner Transcatheter Heart Valve study. Eur Heart J 2011;32:148–157.
    1. Anker SD, Agewall S, Borggrefe M, Calvert M, Jaime Caro J, Cowie MR, Ford I, Paty JA, Riley JP, Swedberg K, Tavazzi L, Wiklund I, Kirchhof P. The importance of patient‐reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. Eur Heart J 2014;35:2001–2009.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa